You are here:   Videos
Register   |  Login

Get Adobe Flash player Install latest flash player if this video gallery doesn't work.
Update on JAK Inhibitor — Spleen Volume Reduction and OS interview with Srdan Verstovsek, MD, PhD, at ASH 2011
At the American Society of Hematology (ASH) 2011, Srdan Verstovsek, MD, PhD, discusses the results of the COMFORT I Study, which included consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups as well as overall survival advantage. Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib to those of a historical control group is also discussed.

Accompanying this interview are two downloadable slide decks of the abstracts.
Recent Video
| 
Most Viewed
Tumor Type : Search :